牙周基础治疗对脑卒中高危人群伴中重度牙周炎患者血清 sCD40L及牙周临床指标的影响

上海口腔医学 ›› 2016, Vol. 25 ›› Issue (5): 574-578.

牙周基础治疗对脑卒中高危人群伴中重度牙周炎患者血清 sCD40L及牙周临床指标的影响

高磊¹, 孙晓菊², 谢洪², 南顺花³, 谢慧心⁴

1.大连医科大学,辽宁大连 116044；
2.辽宁省人民医院口腔科,辽宁沈阳 110016；
3.齐齐哈尔医学院附属第三医院口腔科,黑龙江齐齐哈尔 161099；
4.中国医科大学口腔医学院,辽宁沈阳 110002

收稿日期:2016-02-22 修回日期:2016-04-27 出版日期:2016-10-25 发布日期:2016-11-10
通讯作者: 孙晓菊,E-mail：xiaojusun@sina.com
作者简介:高磊（1986-）,女,硕士,医师,E-mail: 1061305663@qq.com
基金资助:
辽宁省科学事业公益研究基金（201507）; 沈阳市科技计划项目（F14-158-9-04）

Effects of essential periodontal treatment on serum level of sCD40L and periodontal clinical parameters in patients with moderate to severe periodontitis at high risk of stroke

GAO Lei¹, SUN Xiao-ju², XIE Hong², NAN Shun-hua³, XIE Hui-xin⁴

1.Dalian Medical University.Dalian 116044,Liaoning Province;
2.Department of Stomatology,People's Hospital of Liaoning Province.Shenyang 110016,Liaoning Province;
3.Department of Stomatology,the Third Affiliated Hospital of Qiqihar Medical University.Qiqihar 161099,Heilongjiang Province;
4.School of Stomatology,China Medical University.Shenyang 110002,Liaoning Province,China

Received:2016-02-22 Revised:2016-04-27 Online:2016-10-25 Published:2016-11-10

摘要/Abstract

摘要： 目的观察脑卒中高危人群伴中重度牙周炎患者治疗前、后血清可溶性白细胞分化抗原配体（soluble CD40 ligand,sCD40L)水平的变化,探讨牙周基础治疗对脑卒中高危人群伴中重度牙周炎患者的影响。方法收集脑卒中高危人群伴中重度牙周炎患者76例,随机分为2组。A组40例,接受牙周基础治疗+相应的常规维持治疗;B组36例,仅接受常规维持治疗。另选取单纯中重度牙周炎患者36例,设为C组,接受牙周基础治疗。分别在治疗前和治疗后3个月由同一名口腔医师检查全口牙6个位点的探诊出血（bleeding on probing,BOP)、牙周探诊深度（probing depth,PD）、附着丧失（attachment loss,AL),用酶联免疫吸附反应法（ELISA)检测血清sCD40L水平。采用SPSS17.0软件包对数据进行统计学分析。结果与治疗前相比,3组患者血清sCD40L水平及牙周临床指标均下降;与B组相比,A组下降更加明显,具有显著差异（P<0.05）。结论牙周基础治疗能降低脑卒中高危人群伴中重度牙周炎患者血清sCD40L水平,改善机体的炎症状态,在一定程度上降低脑卒中高危人群向脑卒中发展的风险。

关键词: 牙周基础治疗, 脑卒中高危人群, 中重度牙周炎, sCD40L, 牙周临床指标

Abstract: PURPOSE: To investigate the effect of periodontal treatment on patients with moderate to severe periodontitis at high risk of stroke, by detecting the level of serum soluble cell differentiation antigen 40 ligand (sCD40L) before and after periodontal non-surgical treatment. METHODS: Seventy-six patients with moderate to severe periodontitis at high risk of stroke were collected and randomly divided into 2 groups, 40 patients in group A received essential periodontal treatment + routine maintenance therapy, 36 cases in group B only received routine maintenance therapy. Another 36 patients with moderate and severe periodontitis were selected as group C, and received essential periodontal treatment. Bleeding on probing (BOP), periodontal probing depth (PD) and attachment loss (AL) in 6 loci were examined by the same dentists, and enzyme linked immunosorbent assay (ELISA) was used to detect the level of serum sCD40L before treatment and 3 months after treatment. The data were analyzed by SPSS 17.0 software package. RESULTS: Compared with pre-treatment, serum level of sCD40L and periodontal clinical indexes of the three groups decreased. Compared with group B, serum SCD40L in group A significantly decreased(P<0.05). CONCLUSIONS: Periodontal treatment can reduce the serum level of sCD40L in patients with moderate to severe periodontitis at high risk of stroke, and improve the patient's inflammatory state. To a certain extent, periodontal treatment may reduce the risk of high-risk stroke population to develop stroke.

Key words: Essential periodontal treatment, Patients with high risk of stroke, Moderate to severe periodontitis, sCD40 ligand (sCD40L), Periodontal clinical parameters

中图分类号:

R781.4

高磊, 孙晓菊, 谢洪, 南顺花, 谢慧心. 牙周基础治疗对脑卒中高危人群伴中重度牙周炎患者血清 sCD40L及牙周临床指标的影响[J]. 上海口腔医学, 2016, 25(5): 574-578.

GAO Lei, SUN Xiao-ju, XIE Hong, NAN Shun-hua, XIE Hui-xin. Effects of essential periodontal treatment on serum level of sCD40L and periodontal clinical parameters in patients with moderate to severe periodontitis at high risk of stroke[J]. Shanghai Journal of Stomatology, 2016, 25(5): 574-578.

参考文献

[1] 孟焕新. 牙周病学[M].第4版.北京: 人民卫生出版社, 2012: 12.
[2] 陈红岩, 孙晓菊, 谢洪, 等. 慢性牙周炎与脑血栓形成相关性研究 [J]. 中国实用口腔科杂志, 2010, 3(3): 164-166.
[3] Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction [J]. Periodontol 2000, 1997, 14: 9-11.
[4] Teng YT. The role of acquired immunity and periodontal disease progression [J]. Crit Rev Oral Biol Med, 2003, 14(4): 237-252.
[5] Yamazaki K, Yoshie H, Seymour GJ. T cell regulation of the immune response to infection in periodontal diseases [J]. Histol Histopathol, 2003, 18(3): 889-896.
[6] Mathur A, Michalowicz BS. Cell-mediated immune system regulation in periodontal diseases [J]. Crit Rev Oral Biol Med, 1997, 8(1): 76-89.
[7] Chaturvedi R, Gupta M, Jain A, et al. Soluble CD40 ligand: a novel biomarker in the pathogenesis of periodontal disease [J]. Clin Oral Investig, 2015, 19(1): 45-52.
[8] Schönbeck U, Mach F, Libby P. CD154 (CD 40 ligand )[J]. Int J Biochem Cell Biol, 2000, 32(30): 687-693.
[9] Freedman JE. CD40-CD40L and platelet function: beyond hemostasis [J]. Circ Res, 2003, 92(9): 944-946.
[10] Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells [J]. Nature, 1998, 391(6667): 591-594.
[11] André P, Prasad KS, Denis CV, et al. CDL stabilizes artefial thrombi by a 63 integrin-dependent mechanism [J]. Nat Med, 2002, 8(3): 247-252.
[12] Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system [J]. Proc Natl Acad Sci USA, 2000, 97(13): 6930-6932.
[13] Zhou L, Stordeur P, de Lavareille A, et al. CD40 engagement on endothelial cells promotes tissue factor dependent procoagulant activity [J]. Thromb Haemostat, 1998, 79(5): 1025-1028.
[14] Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes[J]. N Engl J Med, 2003, 348(12): 1104-1111.
[15] Balla J, Magyar MT, Bereczki D, et al. Serum levels of platelet released CD40 ligand are increased in early onset occlusive carotid artery disease [J]. Dis Markers, 2006, 22(3): 133-140.
[16] Schönbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women [J]. Circulation, 2001, 104(19): 2266-2268.
[17] 陈亚锋, 邓长金, 胡迎富, 等.普伐他汀对高胆固醇血症患者CD40配体的影响 [J].微循环学杂志, 2009, 19(1): 31-33.
[18] 黄载文. 缺血性脑卒中的危险因素研究进展 [J]. 中国医药指南, 2013, 11(11): 60-61.
[19] 曹承兰, 余年, 林兴建, 等. 脑卒中高危人群的相关危险因素 [J].临床神经病学杂志, 2014, 27(5): 335-337.
[20] Mach F, Schönbeck U, Sukhova GK, et al. Functional CD40 and is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40 ligand signaling in atherosclerosis [J]. Proc Natl Acad Sci USA, 1997, 94(5): 1931-1936.
[21] Häkkinen T, Karkola K, Ylä-Herttuala S, et al. Macrophages, smooth muscle cells, endothelial cells, and T cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Coloealization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CDl6 (Fc gammaRIII) [J]. Virchows Arch, 2000, 437(4): 396-405.
[22] Schönbeck U, Mach F, Sukhoa GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth cells by T lymphocytes: a role for CD40 signaling in plaque rupture [J]. Circ Res, 1997, 81(3): 448-454.
[23] Sehönbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice [J]. Proc Natl Acad Sci USA, 2000, 97(13): 7458-7463.
[24] Papapanagiotou D, Nicu EA, Bizzarro S, et al. Periodontitis is associated with platelet activation[J]. Atherosclerosis, 2009, 202(2): 605-611.
[25] Angulo P. Nonalcoholic fatty liver disease [J]. N Engl J Med, 2002, 346(16): 1221-1231.
[26] Herm V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells [J]. Nature, 1998, 391(6667): 591-594.